版本:
中国

BRIEF-FDA grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma

May 1 U.S. FDA

* Grants accelerated approval to Durvalumab for treatment of patients with locally advanced or metastatic urothelial carcinoma

* Approved Ventana PD-l1 assay as complementary diagnostic for assessment of PD-l1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue Source text : [ID:bit.ly/2oYipOi] Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐